ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
AI-Designed TREM1-Targeted LYTAC Nanoparticles Reprogram the Neuroimmune Microenvironment in Traumatic Brain Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Secondary neuroinflammation drives progressive damage after traumatic brain injury (TBI), but therapeutics that modulate key inflammatory amplifiers remain limited. Here, we identify infiltrating macrophages as the predominant TREM1-expressing population in TBI human and mouse brain and show that TREM1 deletion attenuates neuroinflammation, preserves neurovascular integrity, and improves neurological and behavioral recovery after TBI. To develop a pharmacological strategy, we designed a de novo TREM1-binding peptide, converted it into a mannose-6-phosphate lysosome-targeting chimera (LYTAC), and delivered it using an Angiopep-2-functionalized, pH-responsive dendrimer nanoparticle. This Angiopep-2/PAMAM/TPA/LYTAC nanoparticle (APTL-NP) enhanced brain delivery, promoted lesion-responsive payload release, reduced TREM1 protein abundance in vivo, and outperformed free degrader and LP17 in suppressing inflammatory mediators, edema, blood-brain barrier disruption, neuronal apoptosis, and behavioral deficits. Single-cell transcriptomics suggested remodeling of myeloid, astrocytic, vascular, and SPP1/CXCL-associated communication programs. These findings support targeted TREM1 reduction as a strategy for modulating secondary TBI injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.